[Skip to Navigation]
Views 910
Citations 0
Comment & Response
April 22, 2020

Effect Size and Blinding in Lumateperone Trial

Author Affiliations
  • 1Department of Psychiatry, Boston University Medical Center, Boston, Massachusetts
  • 2Mental Health Service Line, Edith Nourse Rogers Memorial VA Medical Center, Bedford, Massachusetts
  • 3Departments of Psychiatry and Quantitative Health Sciences, University of Massachusetts Medical School, Worcester
JAMA Psychiatry. 2020;77(6):650-651. doi:10.1001/jamapsychiatry.2020.0610

To the Editor The article “Efficacy and Safety of Lumateperone for Treatment of Schizophrenia: A Randomized Clinical Trial”1 by Correll and colleagues was notable for its thorough data analyses (including multiple sensitivity analyses of the primary outcome) and for the relatively low rate of both negative metabolic effects and extrapyramidal symptoms observed with lumateperone. These 2 classes of adverse events have been associated with treatment nonadherence in this vulnerable patient population.2

Limit 200 characters
Limit 25 characters
Conflicts of Interest Disclosure

Identify all potential conflicts of interest that might be relevant to your comment.

Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.

Err on the side of full disclosure.

If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.

Not all submitted comments are published. Please see our commenting policy for details.

Limit 140 characters
Limit 3600 characters or approximately 600 words
    ×